Jubilant Pharmova Limited has informed the Exchange about Other Restructuring

Strategic Transactions View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.6%Reaction day

₹1121.20

prior close

₹1060.50

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-2.2% vs market

Pharmaceuticals peers, median of 148sector-0.5%-2.1% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.3

10m

+6.4

15m

+6.8

30m

+8.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.6-0.4-2.2-0.5-2.1

Next day

+0.6+0.1+0.5-0.6+1.2

-0.1-0.6+0.5-1.8+1.7

+0.5-0.8+1.3-2.6+3.1

+0.4-2.7+3.1-4.0+4.4

-1.3-2.1+0.8-3.6+2.4

-0.1-0.6+0.5-3.1+2.9

15d

+6.8+2.8+4.0-0.2+7.1

+6.5+3.1+3.4-0.2+6.7

-4.0-3.2-0.9-4.5+0.4

-0.2-0.1-0.1-3.4+3.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova's board approved the transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary, on a slump sale basis. The API business contributed Rs. 609 crore in turnover (8.35% of consolidated revenue) and had a net worth of Rs. 666.5 crore (10.68% of consolidated net worth) for FY25. The deal was signed on June 12, 2025, and is expected to complete by September 1, 2025, subject to lender and shareholder approvals. The purchase consideration will be based on book value as of the appointed date (per Income Tax Rule 11UAE) and will be discharged primarily through issuance of shares by JBL. The move aims to house drug discovery and CDMO API services under one entity, creating an end-to-end CRDMO platform under the Jubilant Biosys brand.

Likely market impact

Since the buyer is a wholly-owned subsidiary and consideration is paid mainly in shares, shareholders' overall economic interest remains unchanged — this is an internal restructuring rather than a true divestiture. Operational synergies and better asset utilisation are expected, but near-term stock reaction is likely to be neutral.